{"id":"https://openalex.org/W4416639083","doi":"https://doi.org/10.1183/13993003.congress-2025.pa3667","title":"EGPA disease burden in Europe and US: evidence from real-world clinical practice","display_name":"EGPA disease burden in Europe and US: evidence from real-world clinical practice","publication_year":2025,"publication_date":"2025-09-27","ids":{"openalex":"https://openalex.org/W4416639083","doi":"https://doi.org/10.1183/13993003.congress-2025.pa3667"},"language":"en","primary_location":{"id":"doi:10.1183/13993003.congress-2025.pa3667","doi":"https://doi.org/10.1183/13993003.congress-2025.pa3667","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2025.pa3667","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Allergy and immunology","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5071614104","display_name":"Bo Ding","orcid":"https://orcid.org/0000-0001-9131-4563","observed_orcids":["https://orcid.org/0000-0001-9131-4563"]},"institutions":[{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Bo Ding","raw_affiliation_strings":["1BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden","institution_ids":["https://openalex.org/I4210143795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004355994","display_name":"Robert Spiera","orcid":"https://orcid.org/0000-0003-2911-6800","observed_orcids":["https://orcid.org/0000-0003-2911-6800"]},"institutions":[{"id":"https://openalex.org/I1281539108","display_name":"Hospital for Special Surgery","ror":"https://ror.org/03zjqec80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1281539108"]},{"id":"https://openalex.org/I205783295","display_name":"Cornell University","ror":"https://ror.org/05bnh6r87","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295"]},{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Spiera","raw_affiliation_strings":["2Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, United States","institution_ids":["https://openalex.org/I1281539108","https://openalex.org/I205783295","https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111942908","display_name":"Paul Dolin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Paul Dolin","raw_affiliation_strings":["3BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005723446","display_name":"Lotte Westerink","orcid":"https://orcid.org/0000-0001-9515-1044","observed_orcids":["https://orcid.org/0000-0001-9515-1044"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Lotte Westerink","raw_affiliation_strings":["4Health Economics and Payer Evidence, AstraZeneca, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Health Economics and Payer Evidence, AstraZeneca, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Chris Edmonds","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chris Edmonds","raw_affiliation_strings":["5Market Access and Pricing, AstraZeneca, Gaithersburg, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Market Access and Pricing, AstraZeneca, Gaithersburg, United States","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080267206","display_name":"Danuta Kielar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Danuta Kielar","raw_affiliation_strings":["3BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055768910","display_name":"Oliver-Thomas Carter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091464","display_name":"Adelphi Group (United Kingdom)","ror":"https://ror.org/00egpfv87","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210091464"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Oliver-Thomas Carter","raw_affiliation_strings":["6Adelphi Real World, Bollington, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Adelphi Real World, Bollington, United Kingdom","institution_ids":["https://openalex.org/I4210091464"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5099138965","display_name":"Tia Pennant","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091464","display_name":"Adelphi Group (United Kingdom)","ror":"https://ror.org/00egpfv87","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210091464"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Tia Pennant","raw_affiliation_strings":["6Adelphi Real World, Bollington, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Adelphi Real World, Bollington, United Kingdom","institution_ids":["https://openalex.org/I4210091464"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012420519","display_name":"Fritha Hennessy","orcid":"https://orcid.org/0000-0002-3387-5423","observed_orcids":["https://orcid.org/0000-0002-3387-5423"]},"institutions":[{"id":"https://openalex.org/I4210091464","display_name":"Adelphi Group (United Kingdom)","ror":"https://ror.org/00egpfv87","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210091464"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Fritha Hennessy","raw_affiliation_strings":["6Adelphi Real World, Bollington, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Adelphi Real World, Bollington, United Kingdom","institution_ids":["https://openalex.org/I4210091464"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5013467404","display_name":"Stephanie Yanjing Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephanie Yanjing Chen","raw_affiliation_strings":["7BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, United States","institution_ids":["https://openalex.org/I4210150756"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"PA3667","last_page":"PA3667"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10697","display_name":"Vasculitis and related conditions","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10697","display_name":"Vasculitis and related conditions","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12600","display_name":"Eosinophilic Disorders and Syndromes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/eosinophilic-granulomatosis-with-polyangiitis","display_name":"eosinophilic granulomatosis with polyangiitis","score":0.9990000128746033},{"id":"https://openalex.org/keywords/disease-burden","display_name":"disease burden","score":0.8669999837875366},{"id":"https://openalex.org/keywords/vasculitis","display_name":"vasculitis","score":0.9520000219345093},{"id":"https://openalex.org/keywords/organ-damage","display_name":"organ damage","score":0.8370000123977661},{"id":"https://openalex.org/keywords/asthma-exacerbations","display_name":"asthma exacerbations","score":0.8759999871253967},{"id":"https://openalex.org/keywords/hospitalization","display_name":"hospitalization","score":0.9700000286102295},{"id":"https://openalex.org/keywords/pulmonary-involvement","display_name":"pulmonary involvement","score":0.7540000081062317},{"id":"https://openalex.org/keywords/real-world-clinical-practice","display_name":"real-world clinical practice","score":0.578000009059906}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9189000129699707},{"id":"https://openalex.org/C2776042228","wikidata":"https://www.wikidata.org/wiki/Q35869","display_name":"Asthma","level":2,"score":0.7228999733924866},{"id":"https://openalex.org/C2777014857","wikidata":"https://www.wikidata.org/wiki/Q1383410","display_name":"Exacerbation","level":2,"score":0.6588000059127808},{"id":"https://openalex.org/C2781229154","wikidata":"https://www.wikidata.org/wiki/Q1161568","display_name":"Granulomatosis with polyangiitis","level":4,"score":0.6345000267028809},{"id":"https://openalex.org/C2779758542","wikidata":"https://www.wikidata.org/wiki/Q2106364","display_name":"Eosinophilic","level":2,"score":0.5358999967575073},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4510999917984009},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.4194999933242798},{"id":"https://openalex.org/C2779974597","wikidata":"https://www.wikidata.org/wiki/Q28448986","display_name":"Clinical Practice","level":2,"score":0.38449999690055847},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3772999942302704},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.36820000410079956},{"id":"https://openalex.org/C2909082789","wikidata":"https://www.wikidata.org/wiki/Q35869","display_name":"Asthma exacerbations","level":3,"score":0.35910001397132874},{"id":"https://openalex.org/C2780664029","wikidata":"https://www.wikidata.org/wiki/Q5282120","display_name":"Disease burden","level":3,"score":0.35589998960494995},{"id":"https://openalex.org/C2776015282","wikidata":"https://www.wikidata.org/wiki/Q644318","display_name":"Vasculitis","level":3,"score":0.3513999879360199},{"id":"https://openalex.org/C2776178081","wikidata":"https://www.wikidata.org/wiki/Q3286546","display_name":"Respiratory disease","level":3,"score":0.31679999828338623},{"id":"https://openalex.org/C2993312423","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medical practice","level":2,"score":0.3037000000476837},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2890999913215637},{"id":"https://openalex.org/C195910791","wikidata":"https://www.wikidata.org/wiki/Q1324077","display_name":"Medical record","level":2,"score":0.26440000534057617},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.2590000033378601}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1183/13993003.congress-2025.pa3667","doi":"https://doi.org/10.1183/13993003.congress-2025.pa3667","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2025.pa3667","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Allergy and immunology","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4396576986","https://openalex.org/W4312617551","https://openalex.org/W4387982169","https://openalex.org/W7155100906","https://openalex.org/W4311339610","https://openalex.org/W4390754507","https://openalex.org/W4311332949","https://openalex.org/W2775953980","https://openalex.org/W4407132534","https://openalex.org/W4391538695"],"abstract_inverted_index":{"Introduction:":[0],"Eosinophilic":[1],"granulomatosis":[2],"with":[3,14,64,85,171,192,201],"polyangiitis":[4],"(EGPA)":[5],"is":[6],"a":[7,40,86,120],"rare":[8],"vasculitis":[9],"affecting":[10,146],"small-to-medium":[11],"blood":[12],"vessels":[13],"multisystem":[15],"organ":[16,69,143],"involvement.":[17],"This":[18],"retrospective,":[19],"observational,":[20],"real-world":[21],"study":[22],"characterised":[23],"the":[24,32,130,135,147,152,181],"EGPA":[25,36,65,88,165,193],"disease":[26,196],"burden.":[27],"Methods:":[28],"Data":[29],"drawn":[30],"from":[31],"Adelphi":[33],"Real":[34],"World":[35],"Disease":[37],"Specific":[38],"ProgrammeTM,":[39],"cross-sectional":[41],"survey":[42],"of":[43,123,138,184,204],"physicians":[44,93],"and":[45,50,73,113,207],"patients":[46],"(pts)":[47],"in":[48,134,180],"Europe":[49],"US":[51],"conducted":[52],"between":[53],"July\u2013December":[54],"2023":[55],"were":[56,108,111,188],"analysed":[57],"descriptively.":[58],"Physicians":[59],"who":[60],"managed":[61],"\u22652":[62],"pts":[63,81,139,157,169],"reported":[66],"demographics,":[67],"symptoms,":[68],"damage,":[70,144],"asthma":[71,178,205],"exacerbations":[72,206],"hospitalisations":[74],"for":[75],"their":[76],"next":[77],"4\u20135":[78],"consecutively":[79],"consulting":[80],"(\u226510":[82],"years":[83],"old,":[84],"physician-confirmed":[87],"diagnosis).":[89],"Results:":[90],"Overall,":[91],"121":[92],"provided":[94],"data":[95,128],"on":[96],"503":[97],"pts.":[98],"Mean":[99],"(SD)":[100,122],"pt":[101],"age":[102],"was":[103],"50":[104],"(15)":[105],"years,":[106],"50%":[107],"male,":[109],"89%":[110],"White":[112],"22%":[114],"required":[115],"caregiver":[116],"support.":[117],"Pts":[118,191],"had":[119,140,158,176],"mean":[121],"3":[124],"(3)":[125],"symptoms":[126],"at":[127],"capture,":[129],"most":[131],"common":[132],"shown":[133],"Figure.":[136],"72%":[137],"physician-determined":[141],"EGPA-induced":[142],"commonly":[145],"pulmonary":[148],"system":[149],"(Figure).":[150],"In":[151],"past":[153,182],"year,":[154],"72/406":[155],"(18%)":[156],"been":[159],"hospitalised,":[160],"51/72":[161],"(71%)":[162],"due":[163],"to":[164],"complications.":[166],"Of":[167],"277":[168],"(55%)":[170],"concomitant":[172],"asthma,":[173],"83":[174],"(30%)":[175],"an":[177],"exacerbation":[179],"year;":[183],"those,":[185],"20":[186],"(24%)":[187],"hospitalised.":[189],"Conclusion:":[190],"have":[194],"substantial":[195],"burden,":[197],"impacting":[198],"multiple":[199],"organs,":[200],"high":[202],"rates":[203],"hospitalisations.":[208],"erj;66/suppl_69/PA3667/F1":[209],"F1":[210,211]},"counts_by_year":[],"updated_date":"2026-11-01T11:40:01.658920","created_date":"2025-11-25T00:00:00"}